New evaluation of the ESHRE Study into the Evaluation of oocyte Euploidy by Microarray analysis (ESTEEM) has shown that mechanisms other than abnormal chromosome segregation can cause errors during meiosis.

Fertility clinics should tell patients that there is no evidence that assisted hatching works, nor any guarantee that the add-on treatment is risk-free. This information should be provided before offering couples this adjuvant technique.

Fear of failure, high cost, and juggling a job with clinic visits are among many factors that make fertility treatment stressful. What is unclear is whether mental distress is worse for couples who achieve a pregnancy using ART than those who conceive spontaneously.

The responsibility for setting rules on infectious disease screening in MAR will most likely move to the European Centre for Disease Prevention and Control (ECDC) following the current revision of the EU legislation on Substances of Human Origin. To support this process, the ECDC has established a new network and invited ESHRE to participate in its first in-person meeting last week.

Data based on more than 8,000 UK pregnancies show odds of non-live birth almost double for parents-to-be who become unemployed.

Add-ons are defined as supplementary options available to patients in addition to standard fertility procedures, with the common promise of enhancing pregnancy or live birth rates (LBRs), mitigating the risk of miscarriage, or expediting the time to achieving pregnancy (1). However, there is a lack of substantial evidence regarding the safety and efficacy of add-ons.

ESHRE is thrilled to announce an exciting campus workshop, taking place in Maastricht, on the 2nd and 3rd of October. Brought to you by the Special Interest Groups Endometriosis and Endometrial Disorders, and Stem Cells, this workshop will delve into the intricate interplay between the developing embryo and maternal endometrium. We are excited to bring together a panel of prominent experts in the field who will share their latest insights and research findings.

Adding letrozole (LZ) as a co-treatment during ovarian stimulation is safe for IVF patients, according to results from a randomized controlled trial.

The expected key message from this Campus in Lyon on 26 and 27 October is that school curricula globally should include reproductive health education.

The European Society of Human Reproduction and Embryology (ESHRE) is steadfast in its commitment to advancing knowledge, fostering research, and promoting best practices in the field of reproductive medicine and embryology. In alignment with our objectives and in collaboration with global peers, a curated session with ESHRE’s special interest group Global and Sociocultural Aspects of Infertility, at the esteemed 2023 World Congress of the International Federation of Fertility Societies (IFFS) that was held in Athens, Greece, from 10 to 13 September 2023.